



[www.G2Gconsulting.com](http://www.G2Gconsulting.com)

May 2016

Title	Opportunity No.	Description	Deadline	Funding Level	Eligibility	Link
<b>NEURAL SYSTEMS</b>						
DoD Multiple Sclerosis Pilot Clinical Trial Award	W81XWH-16-MSRP-PCTA	The PCTA supports early-phase, proof-of-principle clinical trials to investigate hypothesis-based interventions that have potential to result in profound impact on management of MS symptoms. Therapeutic approaches may include therapies already in clinical use, or undergoing clinical testing for other diseases, provided that their proposed use for MS would lead to a major advancement for treating one of the disease symptoms.	Pre-application: May 26, 2016  Full Application: Aug. 29, 2016	Total Program Funding: \$1.9 m	Unrestricted	<a href="http://cdmrp.army.mil/funding/pa/16msrppcta_pa.pdf">http://cdmrp.army.mil/funding/pa/16msrppcta_pa.pdf</a>
DoD Multiple Sclerosis Research Program	W81XWH-16-MSRP-IIRA	The IIRA mechanism is offered for research specifically addressing obstacles to remyelination in MS. The IIRA supports highly rigorous, high-impact research projects that have the potential to make an important contribution to MS research and/or patient care. Research projects may focus on any phase of research, excluding clinical trials.	Pre-application: May 26, 2016  Full Application: Aug. 29, 2016	Total Program Funding: \$2.9 m	Unrestricted	<a href="http://cdmrp.army.mil/funding/pa/16msrpiira_pa.pdf">http://cdmrp.army.mil/funding/pa/16msrpiira_pa.pdf</a>
DoD Multiple Sclerosis Exploration-Hypothesis Development Award	W81XWH-16-MSRP-EHDA	The EHDA supports initial exploration of high-risk, high-gain, and potentially groundbreaking concepts in the MS research field. Studies supported by this award mechanism are expected to lay the groundwork for future	Pre-application: May 26, 2016  Full Application: Aug. 29, 2016	Total Program Funding: \$720,000	Unrestricted	<a href="http://cdmrp.army.mil/funding/pa/16msrpehda_pa.pdf">http://cdmrp.army.mil/funding/pa/16msrpehda_pa.pdf</a>

		avenues of scientific investigation. Proposed research project should include a well-formulated, testable hypothesis based on strong scientific rationale and study design.				
DoD Spinal Cord Injury Translational Award	W81XWH-16-SCIRP-TRA	The SCIRP TRA is intended to support translational research that will accelerate the movement of promising ideas in SCI research into clinical applications. Examples include demonstration studies of pharmaceuticals and medical devices in preclinical systems, and/or clinical research on therapeutics, devices, or practice using human tissues or resources.	Pre-application: June 21, 2016  Full Application: Sept. 21, 2016	Program Funding: \$6 m  Award Ceiling: \$1.25 m	Unrestricted	<a href="http://cdmrp.army.mil/funding/pa/16scirptra_pa.pdf">http://cdmrp.army.mil/funding/pa/16scirptra_pa.pdf</a>
DoD Spinal Cord Injury Qualitative Award	W81XWH-16-SCIRP-QRA	The intent of the Qualitative Research Award is to support qualitative research studies that will help researchers and clinicians better understand the experiences of individuals with SCI and thereby identify the most effective paths for adjusting to disability and/or improving overall quality of life, health, and functional status after SCI.	Pre-application: June 21, 2016  Full Application: Sept. 21, 2016	Program Funding: \$3.2 m  Award Ceiling: \$500,000	Unrestricted	<a href="http://cdmrp.army.mil/funding/pa/16scirpqa_pa.pdf">http://cdmrp.army.mil/funding/pa/16scirpqa_pa.pdf</a>
DoD Neurofibromatosis Clinical Consortium Award	W81XWH-16-NFRP-CCA	This FOA is intended to support a major goal/product-driven Consortium of exceptional institutions and investigators that will accelerate the clinical translation of basic NF research and ultimately decrease the impact of the disease. The objectives of the Consortium shall be to conceive, design, develop, and conduct collaborative Phase I and II clinical evaluations of promising therapeutic agents for the management or treatment of NF1, NF2, and schwannomatosis.	Pre-application: June 8, 2016  Full Application: Aug. 1, 2016	Total Program Funding: \$5 m	Unrestricted	<a href="http://cdmrp.army.mil/funding/pa/16nfrpcca_pa.pdf">http://cdmrp.army.mil/funding/pa/16nfrpcca_pa.pdf</a>
DoD Neurofibromatosis	W81XWH-16-	Clinical trials supported by	Pre-	Total Program	Unrestricted	<a href="http://cdmrp.">http://cdmrp.</a>

Clinical Trial Award	NFRP-CTA	this FOA may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials to demonstrate feasibility or inform the design of more advanced trials, through large-scale trials to determine efficacy in relevant patient populations.	application: July 18, 2016  Full Application: Aug. 1, 2016	Funding: \$1.44 m		<a href="http://army.mil/funding/pa/16nfrpcta_pa.pdf">army.mil/funding/pa/16nfrpcta_pa.pdf</a>
DoD Neurofibromatosis Investigator-Initiated Research Award	W81XWH-16-NFRP-IIRA	The NFRP Investigator-Initiated Research Award supports highly rigorous, high-impact research projects that have the potential to make an important contribution to NF research and/or patient care. Research projects may focus on any phase of research, excluding clinical trials.	Pre-application: July 18, 2016  Full Application: Aug. 1, 2016	Total Program Funding: \$1.68 m	Unrestricted	<a href="http://cdmrp.army.mil/funding/pa/16nfrpiira_pa.pdf">http://cdmrp.army.mil/funding/pa/16nfrpiira_pa.pdf</a>
DoD Neurofibromatosis New Investigator Award	W81XWH-16-NFRP-NIA	The intent of the NFRP New Investigator Award is to support the development of promising independent investigators and/or the transition of established investigators from other research fields into a career in the field of NF research. Prior experience in NF research not required. PIs with a limited background in NF research are strongly encouraged to have a collaborator who is experienced in the NF field.	Pre-application: July 18, 2016  Full Application: Aug. 1, 2016	Total Program Funding: \$2.88 m  Award Ceiling: \$450,000	Unrestricted	<a href="http://cdmrp.army.mil/funding/pa/16nfrpnia_pa.pdf">http://cdmrp.army.mil/funding/pa/16nfrpnia_pa.pdf</a>
DoD Tuberous Sclerosis Complex Exploration-Hypothesis Development Award	W81XWH-16-TSCRPEHDA	The EHDA supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the TSC research field. The proposed research project should include a well-formulated, testable hypothesis based on strong scientific rationale and study design.	Pre-application: July 1, 2016  Full Application: July 18, 2016	Program Funding: \$1.6 m  Award Ceiling: \$200,000	Unrestricted	<a href="http://cdmrp.army.mil/funding/pa/16tscrp ehda_pa.pdf">http://cdmrp.army.mil/funding/pa/16tscrp ehda_pa.pdf</a>

DoD Tuberous Sclerosis Idea Development Award	W81XWH-16-TSCR-IDA	The IDA promotes ideas that have the potential to yield high-impact findings and new avenues of investigation. This award mechanism supports conceptually innovative research that could ultimately lead to critical discoveries in TSC research and/or improvements in patient care. Research projects should include a well-formulated, testable hypothesis based on strong preliminary data and scientific rationale.	Pre-application: July 1, 2016  Full Application: July 18, 2016	Program Funding: \$1.44 m  Award Ceiling: \$450,000	Unrestricted	<a href="http://cdmrp.army.mil/funding/pa/16tscrpida_pa.pdf">http://cdmrp.army.mil/funding/pa/16tscrpida_pa.pdf</a>
DoD FY16 Tuberous Sclerosis Complex Synergistic Idea Development Award	W81XWH-16-TSCR-SIDA	The TSCR Synergistic Idea Development Award mechanism is being offered for the first time in FY16. The Synergistic Idea Development Award supports new or existing partnerships between two or three PIs who should utilize their complementary and synergistic perspectives to significantly accelerate advances in TSC research to support the TSCR vision to lessen the impact of TSC.	Pre-application: July 1, 2016  Full Application: July 18, 2016	Program Funding: \$1.2 m  Award Ceiling: \$750,000	Unrestricted	<a href="http://cdmrp.army.mil/funding/pa/16tscrpida_pa.pdf">http://cdmrp.army.mil/funding/pa/16tscrpida_pa.pdf</a>
DoD FY16 Tuberous Sclerosis Complex Pilot Clinical Trial Award	W81XWH-16-TSCR-PCTA	The PCTA mechanism supports exploratory studies involving limited human exposure that produce information on diagnostic or therapeutic effectiveness, safety, tolerability, or mechanisms of action. These studies should be aimed at obtaining preliminary data leading to the development of interventions with the potential to improve TSC outcomes.	Pre-application: July 1, 2016  Full Application: July 18, 2016	Program Funding: \$480,000  Award Ceiling: \$300,000	Unrestricted	<a href="http://cdmrp.army.mil/funding/pa/16tscrpcta_pa.pdf">http://cdmrp.army.mil/funding/pa/16tscrpcta_pa.pdf</a>
DoD Tuberous Sclerosis Complex Postdoctoral Development Award	W81XWH-16-TSCR-PDA	The Postdoctoral Development Award supports recent doctoral or medical graduates to conduct impactful research with the mentorship of an experienced TSC researcher. This opportunity allows for junior investigators to develop and	Pre-application: July 1, 2016  Full Application:	Total Program Funding: \$720,000  Award Ceiling: \$150,000	Unrestricted	<a href="http://cdmrp.army.mil/funding/pa/16tscrpda_pa.pdf">http://cdmrp.army.mil/funding/pa/16tscrpda_pa.pdf</a>

		investigate a TSC research project and further their intellectual development as a TSC researcher of the future.	July 18, 2016			
Connectomes Related to Human Disease (U01)-NIH	PAR-14-281	This Funding Opportunity Announcement (FOA) invites applications to build on the data collected using the very well defined experimental protocols of the Human Connectome Project (HCP). Applications are sought that will apply the Human Connectome data collection protocol to disease/disorder cohorts of interest to the Institutes and Centers that are participating in this FOA. These cohorts will be defined by the applicant and can include subjects with specific symptoms or conditions, with comorbid conditions, with a specific genetic profile, or other applicant defined criteria.	July 14, 2016	In 2010, \$40M was awarded to 2 major cooperative agreements (Washington University, University of Minnesota).	Unrestricted	<a href="http://grants.nih.gov/grants/guide/pa-files/PAR-14-281.html">http://grants.nih.gov/grants/guide/pa-files/PAR-14-281.html</a> , <a href="http://www.neuroscienceblueprint.nih.gov/connectome/">http://www.neuroscienceblueprint.nih.gov/connectome/</a>
NIH Impact of Aging in Human Cell Models of Alzheimer's Disease (R01)	RFA-AG-17-009	The goal of this FOA is to establish the impact of aging on the expression and/or modulation of AD pathological processes and to assess age-related AD genotype-phenotype relationships in human cell models. Research incorporating different brain cell types to promote neural circuit maturation and complexity in such cell models is expected to better recapitulate and give greater insight into AD pathological processes.	Letters of Intent Due: Aug. 28, 2016  Applications Due: Sept. 28, 2016	Total Program Funding: \$2.25 m  Award Ceiling: \$250,000	Unrestricted	<a href="http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-17-009.html">http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-17-009.html</a>
NIH From Association to Function in the Alzheimers Disease Post Genomics Era (R21)	RFA-AG-17-011	This FOA solicits early stage innovative and exploratory research focused on understanding the structure and function of proteins or protein complexes regulated by different AD genetic variants that have been identified to be associated with the sporadic and late onset Alzheimers.	Sept. 27, 2016	Program Funding: \$1 m  Award Ceiling: \$200,000	Unrestricted	<a href="http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-17-011.html">http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-17-011.html</a>
NIH R01 Companion Opportunity	RFA-AG-17-010	This is the R01 companion	Sept. 27, 2016	Program Funding: \$4 m	Unrestricted	<a href="http://grants.nih.gov/grant">http://grants.nih.gov/grant</a>

		opportunity to the above.		Award Ceiling: \$350,000		<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-17-010.html">s/guide/rfa-files/RFA-AG-17-010.html</a>
BRAIN Initiative: Optimization of Novel Tools and Technologies for Neuroscience Research (R44) Department of Health and Human Services National Institutes of Health	PAR-15-121	In this FOA we seek applications through SBIR for the optimization of existing and emerging technologies and approaches including 1) technologies and novel approaches for large scale recording and manipulation of neural activity, at or near cellular resolution, at multiple spatial and/or temporal scales, in any region and throughout the entire depth of the brain, 2) tools to facilitate the detailed analysis of complex circuits and provide insights into cellular interactions that underlie brain function. This FOA is intended for the iterative refinement of emergent technologies and approaches that have already demonstrated their transformative potential through initial proof-of-concept testing, and are appropriate for accelerated development with an end-goal of broad dissemination and incorporation into regular neuroscience practice.	Jan. 5, 2017	\$150,000 for Phase I awards  \$1,000,000 for Phase II awards.	Small businesses	<a href="http://grants.nih.gov/grants/guide/pa-files/PA-15-121.html">http://grants.nih.gov/grants/guide/pa-files/PA-15-121.html</a>
Neuroscience Research on Drug Abuse (three separate grants) a. (R03) b. (R-21) c. (R-01)	a. PA-13-336 b. PA-13-337 c. PA-13-338	Substance abuse results in widespread changes in brain structure and function, and research is needed to explain these changes and how they affect behavior.	Jan. 7, 2017	Award Ceiling: \$100,000	Governments, Nonprofits, educational institutions, small businesses	<a href="http://grants.nih.gov/grants/guide/pa-files/PA-13-336.html">http://grants.nih.gov/grants/guide/pa-files/PA-13-336.html</a>
NINDS Direct Phase II SBIR Grants to Support Exploratory Clinical Trials	PAR-14-265	The purpose of this funding opportunity announcement (FOA) is to encourage exploratory clinical trial applications to the newly authorized Direct-to-Phase II SBIR grant mechanism. The projects must focus on products related to the mission and goals of the National Institute of Neurological Disorders and Stroke (NINDS) and may evaluate drugs, biologics, devices, or diagnostics, as well as surgical, behavioral or	Jan. 7, 2017	\$1,000,000 for Phase II awards	Small Businesses	<a href="http://grants.nih.gov/grants/guide/pa-files/PA-14-265.html">http://grants.nih.gov/grants/guide/pa-files/PA-14-265.html</a>

		<p>rehabilitation therapies. Applications are invited from eligible United States small business concerns (SBCs) that have demonstrated the scientific and technical merit and feasibility of the prototype stage of developing a biomedical technology that has commercial potential, RandD that is characteristic of Phase-I (R43) SBIR projects. The Direct-to-Phase II grant mechanism is intended to facilitate SBIR-type RandD, to expand RandD opportunities for applicant small business concerns (SBCs), and to enhance the pace of technology development and commercialization.</p>				
Brain Somatic Mosaicism and its Role in Psychiatric Disorders (Collaborative U01)	PAR-15-022	<p>This funding opportunity announcement (FOA) invites Cooperative Agreement (U01) applications from multi-disciplinary and synergistic teams of investigators proposing to identify and characterize the full spectrum of somatic variation in human brain samples and to assess the relationship of such variation with the pathophysiology of neuropsychiatric disorders. This FOA seeks to support applications exploring the extent of somatic variations across different brain regions in one or more psychiatric disorders using state-of-the-art genomic, computational, single-cell and other relevant approaches</p>	Feb. 14, 2017	N/A	Unrestricted	<a href="http://grants.nih.gov/grants/guide/pa-files/PAR-15-022.html">http://grants.nih.gov/grants/guide/pa-files/PAR-15-022.html</a>
Alzheimer's Disease Pilot Clinical Trials	PAR-14-089	<p>The objective of the Alzheimer's Disease Pilot Clinical Trials initiative is to enable the clinical testing of promising pharmacological and non-pharmacological interventions in individuals across the Alzheimer's disease spectrum from pre-symptomatic to more severe stages of disease, as well as to stimulate studies to enhance</p>	May 7, 2017	Project determinate. Average funding of \$500,000.	Unrestricted	<a href="http://grants.nih.gov/grants/guide/pa-files/PAR-14-089.html">http://grants.nih.gov/grants/guide/pa-files/PAR-14-089.html</a>

		trial design and methods.				
Neuroimmune Signaling and Function in Substance Use Disorders (R21), (R01)	PA-14-083 PA-14-084	The goal of this area of research is to determine the extent to which neuroimmune responses contribute to or protect against current and future risk and consequences of SUDs.	May 7, 2017	\$200,000	Unrestricted	<a href="http://grants.nih.gov/grants/guide/pa-files/PA-14-083.html">http://grants.nih.gov/grants/guide/pa-files/PA-14-083.html</a>
Novel Tools for Investigating Brain-derived GPCRs in Mental Health Research (R41/R42)(R43/R44)	PA-14-172	See link for description.	May 7, 2017	Not currently listed	Small Business	<a href="http://grants.nih.gov/grants/guide/pa-files/PA-14-172.html">http://grants.nih.gov/grants/guide/pa-files/PA-14-172.html</a>
Lab to Marketplace: Tools for Brain and Behavioral Research (R43/R44)	PA-14-250	The NIH and other research sponsors invest a significant amount of funds in the development of new technologies to study the brain and behavior, from basic and clinical perspectives, through a variety of mechanisms, including, from NIH, the R01, R21, R33, P01, P41, and P50 grants. This investment has produced a large number of technologies that include hardware (e.g., instruments, devices, etc.), software (e.g., computational models, informatics tools, data analytic methods, etc.) and wetware (e.g., cell-free assays, bioactive agents, imaging probes, etc.). While these technologies are put to good use by their developers, such non-commercial developers devote little attention to making their tools robust and easy to use by the broad research community. Consequently, the promise of these advanced technologies is often realized only by the tools' developers and their close associates.	May 7, 2017	\$150,000 for Phase I awards and \$1,000,000 for Phase II awards -	Small Businesses	<a href="http://grants.nih.gov/grants/guide/pa-files/PA-14-250.html">http://grants.nih.gov/grants/guide/pa-files/PA-14-250.html</a>
Neurobiology of Migraine (R21)	PA-14-069	This Funding Opportunity Announcement (FOA) is issued by the National Institute of Neurological Disorders and Stroke (NINDS) in conjunction with the NIH Pain Consortium.	No LOI needed. Due Date: May 7, 2017	No more than \$200,000 per year.	Higher Education, Nonprofits, For profits, Small businesses, Governments.	<a href="http://grants.nih.gov/grants/guide/pa-files/PA-14-069.html">http://grants.nih.gov/grants/guide/pa-files/PA-14-069.html</a>



Temporal Dynamics of Neurophysiological Patterns as Potential Targets for Treating Cognitive Deficits in Brain Disorders (R01) and (R021)	PAR-14-153	A rich body of evidence suggests that cognitive processes are associated with particular patterns of neural activity.	May 7, 2017	Not currently listed.	Unrestricted	<a href="http://grants.nih.gov/grants/guide/pa-files/PAR-14-153.html">http://grants.nih.gov/grants/guide/pa-files/PAR-14-153.html</a>
NINDS CREATE Devices: Translational and Clinical Studies to Inform Final Device Design (UH2/UH3)-NIH	PAR-14-297	The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to pursue translational and clinical studies for therapeutic devices to treat neurological disorders. The program will utilize a cooperative agreement mechanism to support the submission of an Investigational Device Exemption (IDE) or IRB approval for a Non-Significant Risk (NSR) study and the following clinical study. It is expected that the clinical study will inform a final device design that would have to go through most, if not all, of the preclinical testing on the path to more advanced clinical trials and market approval. This program also supports development of a device to test scientific hypotheses that are not feasible or practical to conduct in animal models, but are critical to enable next-generation devices. Activities supported in this program include implementation of clinical prototype devices, preclinical safety and efficacy testing, design verification and validation activities, pursuit of regulatory approval for the clinical study, and a small clinical study.	May 7, 2017	Applicants should rarely exceed \$1M direct costs per year for the UH2 phase and \$1.5M direct costs per year for the UH3 phase.	Unrestricted	<a href="http://grants.nih.gov/grants/guide/pa-files/PAR-14-297.html">http://grants.nih.gov/grants/guide/pa-files/PAR-14-297.html</a>
NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention Infrastructure Resource Access (X01)	PAR-14-253	This FOA encourages requests for access to research resources for multi-site exploratory and confirmatory clinical trials focused on promising interventions, as well as biomarker-or outcome measure validation studies that are immediately preparatory to trials in stroke prevention, treatment, and recovery. Successful	Jul. 12, 2017	Funding levels not currently listed.	Unrestricted	<a href="http://grants.nih.gov/grants/guide/pa-files/PAR-14-253.html">http://grants.nih.gov/grants/guide/pa-files/PAR-14-253.html</a>

		<p>applicants may be given access to the NIH StrokeNet infrastructure. Following peer review, NINDS will prioritize trials among the highest scoring to be given access to the StrokeNet infrastructure. The StrokeNet National Coordinating Center (NCC) will work with the successful applicant to implement the proposed study efficiently. The StrokeNet National Data Management Center (NDMC) will provide statistical and data management support.</p>				
Molecular and Cellular Substrates of Complex Brain Disorders (R01)	PAR-14-309	<p>This Funding Opportunity Announcement (FOA) encourages research grant applications directed toward the discovery of the impact of alterations associated with complex brain disorders on the fundamental cellular and molecular substrates of neuronal function. This funding opportunity encourages the submission of innovative research grant applications at the interface between cellular and molecular mechanisms and that address gaps in understanding the biological mechanisms behind putative disease associated processes with the goal of accelerating progress in emerging research areas relevant to complex brain disorders.</p>	Sept. 7, 2017	<p>Application budgets are not limited but need to reflect the actual needs of the proposed project.</p>	Unrestricted	<p><a href="http://grants.nih.gov/grants/guide/pa-files/PAR-14-309.htm">http://grants.nih.gov/grants/guide/pa-files/PAR-14-309.htm</a></p>
Molecular and Cellular Substrates of Complex Brain Disorders (R21)	PAR-14-310	<p>The R21 activity code is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects.</p>		<p>For R21, direct costs are limited to \$275,000 over a two-year period, with no more than \$200,000 in direct costs allowed in any single year.</p>	Unrestricted	<p><a href="http://grants.nih.gov/grants/guide/pa-files/PAR-14-310.html">http://grants.nih.gov/grants/guide/pa-files/PAR-14-310.html</a></p>
NIH StrokeNet Small Business Innovation Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention	PAR-14-252	<p>This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that</p>	Sept. 7, 2017	<p>\$150,000 for Phase I awards and \$1,000,000 for Phase II</p>	Small Businesses	<p><a href="http://grants.nih.gov/grants/guide/pa-files/PAR-14-252.html">http://grants.nih.gov/grants/guide/pa-files/PAR-14-252.html</a></p>

(U44)		<p>propose exploratory and confirmatory clinical trials focused on promising interventions, as well as biomarker-or outcome measure validation studies that are immediately preparatory to trials in stroke prevention, treatment, and recovery. The program will utilize the cooperative agreement mechanism to enable milestone-drive projects. Successful applicants may be given access to the NIH StrokeNet infrastructure. Following peer review, NINDS will prioritize trials among the highest scoring to be given access to the StrokeNet infrastructure. The StrokeNet National Coordinating Center (NCC) will work with the successful applicant to implement the proposed study efficiently.</p>				
Request to Access Parkinson's Disease Related-Biospecimens (X01)	PAR-14-340	<p>The National Institute of Neurological Disorders and Stroke (NINDS) Parkinson's Disease Biomarkers Program (PDBP), The Michael J. Fox Foundation (MJFF) Parkinson's Disease cohorts and biosample collections, the NINDS-sponsored National Brain and Tissue Resource for Parkinson's Disease and Related Disorders at the Banner Sun Health Research Institute and the Harvard Biomarker Study Biospecimen Repository offer unique biospecimen resources and corresponding clinical data for Parkinson's Disease biomarker discovery, optimization and replication studies. This FOA allows an investigator to apply for access to non-renewable biosamples from one or more of these biosample collections.</p>	Nov. 12, 2017	<p>N/A</p> <p>The number of awards is contingent upon scientific merit and availability of biosample resources.</p>	Unrestricted	<p><a href="http://grants.nih.gov/grants/guide/pa-files/PAR-14-340.html">http://grants.nih.gov/grants/guide/pa-files/PAR-14-340.html</a></p>

<p>BRAIN Initiative: Development, Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (STTR) (R41/R42)</p>	<p>PAR-15-090</p>	<p>The purpose of this funding opportunity announcement (FOA) is to support the development of novel tools and technologies through the Small Business Technology Transfer (STTR) program to advance the field of neuroscience research, including 1) tools to facilitate the detailed analysis of complex circuits and provide insights into cellular interactions that underlie brain function, 2) proof-of-concept testing and development of new technologies and novel approaches for large scale recording and manipulation of neural activity, at or near cellular resolution, at multiple spatial and/or temporal scales, in any region and throughout the entire depth of the brain, and 3) iterative refinement of such tools and technologies with the end-user community with an end-goal of scaling manufacture towards reliable, broad, sustainable dissemination and incorporation into regular neuroscience practice.</p>	<p>Jan. 5, 2018</p>	<p>N/A</p>	<p>Small Businesses</p>	<p><a href="http://grants.nih.gov/grants/guide/pa-files/PAR-15-090.html">http://grants.nih.gov/grants/guide/pa-files/PAR-15-090.html</a></p>
<p>Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems and/or Pharmacodynamic Markers to Facilitate the Discovery of Neurotherapeutics (NIH - R21/R33)</p>	<p>RFA-NS-16-013</p>	<p>The goal of this FOA is to promote a significant improvement in the translational relevance of animal models, ex vivo systems, testing paradigms, and endpoints that will be utilized to facilitate the development of neurotherapeutics. Specifically, this FOA seeks to enable the exploratory and early stages of drug discovery.</p>	<p>Jan. 7, 2018</p>	<p>Estimated Total Program Funding: \$750,000 Award Ceiling: \$250,000</p>	<p>Unrestricted</p>	<p><a href="http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-16-013.html">http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-16-013.html</a></p>
<p>Clinical Trial Readiness for Rare Neurological and Neuromuscular Diseases (NIH - U01)</p>	<p>PAR-16-020</p>	<p>This FOA seeks to support clinical studies that will fill gaps in the design of upcoming clinical trials in rare neurological or neuromuscular diseases by validating clinical outcome measures or biomarkers, or by characterizing cohorts of relevant patients. Through the support of trial readiness</p>	<p>Aug. 17, 2018</p>	<p>Awards dependent on need and funding availability</p>	<p>Unrestricted</p>	<p><a href="http://grants.nih.gov/grants/guide/pa-files/PAR-16-020.html">http://grants.nih.gov/grants/guide/pa-files/PAR-16-020.html</a></p>

		studies, NINDS expects to accelerate the initiation of clinical trials for rare diseases.				
NIH Biomarkers Discovery in Parkinsonism (U01)	PAR-16-112	This FOA encourages biomarkers discovery projects in 1) genetically causal Parkinson's disease, especially for particular sub-types of Parkinson's Disease (PD), including genetic cohorts, biologically defined cohorts of idiopathic PD, or ethnic subgroups of idiopathic PD; 2) The differentiation of synucleinopathies (such as PD and Multiple System Atrophy (MSA) from tauopathies (such as Progressive Supranuclear Palsy and Corticobasal degeneration); or 3) to improve diagnostic differentiation between idiopathic/subtypes of PD and these disorders, as well as from Essential tremor.	Sept. 6, 2018	Contingent upon NIH funding	Unrestricted	<a href="http://grants.nih.gov/grants/guide/pa-files/PA-16-112.html#_Section_II_Award_1">http://grants.nih.gov/grants/guide/pa-files/PA-16-112.html#_Section_II_Award_1</a>
Understanding Alzheimer's Disease in the Context of the Aging Brain (R01)	PAR-15-357	Goal is to establish the role and impact of brain aging in the development and progression of Alzheimers disease (AD). Cross-disciplinary approaches to integrate findings on AD with research on the basic biology and neurobiology of aging are encouraged.	Sept. 7, 2018	Est. Total Program Funding: \$10,000,000	Unrestricted	<a href="http://grants.nih.gov/grants/guide/pa-files/PA-15-357.html">http://grants.nih.gov/grants/guide/pa-files/PA-15-357.html</a>
NIH Research on the Mechanisms and/or Behavioral Outcomes of Multisensory Processing (R01) Department of Health and Human Services	PA-15-347	This FOA supports innovative studies using animal or human subjects to examine two or more senses (visual, auditory, olfactory, gustatory, somatosensory including pain or other submodalities of body senses, and vestibular) for the elucidation of mechanisms and behavioral outcomes of multisensory processing.	Jan. 7, 2019	Will be determined based on applications.	Unrestricted	<a href="http://grants.nih.gov/grants/guide/pa-files/PA-15-347.html#_Section_II_Award_1">http://grants.nih.gov/grants/guide/pa-files/PA-15-347.html#_Section_II_Award_1</a>
Drug Discovery for Nervous System Disorders (NIH - R01)	PAR-16-041	This FOA seeks to stimulate research in the discovery, design, and preclinical testing of innovative and effective therapeutics aimed at prevention or treatment of nervous system disorders of primary interest to the NIMH, NIAAA, and NIDA. Projects	Jan. 7, 2019	Awards dependent on need and funding availability	Unrestricted	<a href="http://grants.nih.gov/grants/guide/pa-files/PA-16-041.html">http://grants.nih.gov/grants/guide/pa-files/PA-16-041.html</a>
Drug Discovery for	PAR-16-042		Jan. 7, 2019			

Nervous System Disorders (NIH - R21)		<p>focused on novel approaches and targets are highly encouraged. The R01 funding data encourages applicants with preliminary data.</p> <p>This R21 grant opportunity is a companion grant, focused on high-risk/high payoff proposals lacking preliminary data.</p>		Award Ceiling: \$200,000	Unrestricted	<a href="http://grants.nih.gov/grants/guide/pa-files/PAR-16-042.html">http://grants.nih.gov/grants/guide/pa-files/PAR-16-042.html</a>
NIH Leveraging Cognitive Neuroscience to Improve Assessment of Cancer Treatment-Related Cognitive Impairment (R21)	PAR-16-213	This FOA encourages transdisciplinary research that will apply cognitive neuroscience theory and task paradigms for improved measurement and assessment of acute- and late-term cognitive changes following cancer treatment for non-central nervous system malignancies.	April 11, 2019	Award Ceiling: \$200,000	Unrestricted	<a href="http://grants.nih.gov/grants/guide/pa-files/PAR-16-213.html">http://grants.nih.gov/grants/guide/pa-files/PAR-16-213.html</a>
R01 Companion Opportunity	PAR-16-212	This FOA is a R01 companion opportunity to the above, aimed at projects in which proof-of-principle of the proposed technology or methodology has already been established and supportive preliminary data are available.	April 11, 2019	Contingent upon NIH funding	Unrestricted	<a href="http://grants.nih.gov/grants/guide/pa-files/PAR-16-212.html#_Section_II._Award_1">http://grants.nih.gov/grants/guide/pa-files/PAR-16-212.html#_Section_II._Award_1</a>
NIH National Institute on Aging (NIA) Late Onset of Alzheimer's Disease (LOAD) Family-Based Study (FBS) (U24)	PAR-16-205	The NIA LOAD FBS began in 2003 with the collection and longitudinal follow up of large multiply affected families under individual NIA investigator awards. This FOA invites applications specific to infrastructure to support the Alzheimer's Disease Sequencing Project related to the collection, longitudinal follow-up, ascertainment of antecedent risk factors, and the characterization of additional relatives from these families.	Sept. 7, 2019	Total Program Funding: \$1.1 m Award Ceiling: \$1.1 m	Unrestricted	<a href="http://grants.nih.gov/grants/guide/pa-files/PAR-16-205.html">http://grants.nih.gov/grants/guide/pa-files/PAR-16-205.html</a>